Key result
GnRH agonists and antagonists show no reported quantitative difference in BNP changes in prostate cancer.
Observational
Abstract lacks quantitative BNP data for GnRH agents; leaves open treatment effects on natriuretic peptides in prostate cancer.
None declared. Table S1. Patient characteristics, pre- and post-treatment BNP levels, and cardiovascular events in patients receiving either GnRH antagonists or agonists. Table S2. Treatment-induced changes in BNP levels in patients with elevated or normal pre-treatment BNP. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Kijima et al. (2020) conducted an observational in Prostate cancer. Gonadotropin-releasing hormone antagonists or agonists was evaluated on Treatment-induced changes in levels of brain natriuretic peptide (BNP). The abstract provides no quantitative results regarding treatment-induced changes in brain natriuretic peptide levels among prostate cancer patients receiving GnRH antagonists or agonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: